slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
talian PowerPoint Presentation
Download Presentation
talian

Loading in 2 Seconds...

  share
play fullscreen
1 / 7
Download Presentation

talian - PowerPoint PPT Presentation

albina
166 Views
Download Presentation

talian

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. www.italiansarcomagroup.org I I talian talian Started June 1997 S S arcoma arcoma G G roup roup Formalized October 2002

  2. 6 8 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 5 3 3 2 1 Italian Sarcoma Group 1 BELGIUM 68 Centers • 14 National Institutes • 14 Universities • 34 Pubblic Hospitals • 6 Private Hospitals 1 1 10 210 members at november 2005

  3. Italian Sarcoma Group Osteosarcoma Protocols •ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts ClosedJCO 2005 • ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 ptsClosedASCO 2005 • ISG/OS I (localized disease) activated 4/2001, 237 pts • EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 120 pts • High risk (relapsed patients) activated 12/2002, 36 pts •H.D. Samarium + PBSCR in multiple bone lesions activated 11/2005, 6 pts

  4. Italian Sarcoma Group Ewing’s Sarcoma Protocols • ISG/SSG III (standard risk) activated 6/99, 264 pts ASCO 2007 • ISG/SSG IV (high risk) activated 6/99, 82 pts ASCO 2005 • ISG/AIEOP (very high risk) activated 12/2002, 25 pts Closed In press EJC 2006 • Relapsed Patients activated 12/2002, 32 pts ASCO 2007 ?

  5. Italian Sarcoma Group Adult soft tissue sarcomas - Protocols • ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk localized disease) with Spanish Group (282 pts) • ISG/STS 03/02 (neodjuvant IFO+RT in retroper. (30 pts) • HD-IFX in continuous infusion (2nd-4th line) (32 pts) • Gemcytabine in leiomyosarcomas (2nd-3rd line) (20 pts) • MiniallogenicTransplant(advanced disease, responsive patients) (6 pts) •Phase 2 Trabectedin in myxoid liposarcoma Other • Imatinib in advanced chordoma (50 pts) (ASCO 2007)

  6. GIST Protocols • • GIOTTO (observational, 2004-2005, in collaboration with Novartis) (790 pts) Closed • • REGISTER (retrospective, histhological) (470 pts) • • 62024 (adjuvant Imatinib), intergroup with EORTC (49/418 pts) • • Institutions from the ISG are participating in the following studies on new agents in GIST: • Sunitinib (international) • •PTK787 (international) • • Nilotinib (international)

  7. In preparation • Osteosarcoma: localized disease • Ewing’s sarcoma: localized disease • Soft tissue sarcomas: high risk, localized • Surgery in GIST after Imatinib (intergroup) • Imatinib in localized chordoma • Imatinib in Chs and fibromatosis